Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00334646 · ClinicalTrials.gov registry record · Phase 1
Cyclophosphamide Drug Interaction Study In Cancer Patients
A Phase 1 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00334646 is a Phase 1 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 25 participants.
The verdict
NCT00334646, a Phase 1 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This study is designed to evaluate the potential pharmacokinetic interaction between oral GW679769 and IV (intravenous) cyclophosphamide when administered to cancer patients.
Interventions
- DRUG Oral GW679769
- DRUG IV Cyclophosphamide 500-700mg/m2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2005-08-10 |
| Est. Completion | 2009-10-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00334646
The ClinicalTrials.gov registry entry for NCT00334646 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oral GW679769 is the first listed.
NCT00334646 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00334646 about?
NCT00334646 is a clinical study titled "Cyclophosphamide Drug Interaction Study In Cancer Patients". This study is designed to evaluate the potential pharmacokinetic interaction between oral GW679769 and IV (intravenous) cyclophosphamide when administered to cancer patients.
What is the current status of trial NCT00334646?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2005-08-10. Estimated completion is 2009-10-14.
What interventions are being tested in trial NCT00334646?
The interventions under investigation include: Oral GW679769 (DRUG), IV Cyclophosphamide 500-700mg/m2 (DRUG).
Who is sponsoring clinical trial NCT00334646?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.